Drug treatment of obesity
by
Bray GA
Pennington Biomedical Research Center,
Baton Rouge, LA, USA.
Baillieres Best Pract Res Clin Endocrinol Metab 1999 Apr;13(1):131-48

ABSTRACT

Drugs to treat obesity can be divided into three groups: those which reduce food intake, those which alter metabolism and those which increase thermogenesis. Monoamines acting on noradrenergic receptors, serotonin receptors, dopamine receptors and histamine receptors can reduce food intake. A number of peptides also affect food intake. The noradrenergic drugs phentermine, diethylpropion, mazindol benzphetamine and phendimetrazine are approved only for short-term use. Sibutramine, a norepinephrine-serotonin re-uptake inhibitor, is approved for long-term use. Orlistat inhibits pancreatic lipase and can block 30% of triglyceride hydrolysis in subjects eating a 30% fat diet. The only thermogenic drug combination that has been tested is ephedrine and caffeine, but this treatment has not been approved by regulating agencies. Leptin is currently in clinical trials and other drugs that may modulate peptide-feeding systems are being developed.

Fen/phen
Anorectics
Synephrine
Sibutramine
Stereotypies
Neurotoxicity
CNS stimulants
Self-medication
Worms on speed
Dopamine uptake
Sleep-deprivation
Canine narcolepsy
Drugs to treat obesity
Appetite suppressants
Fen/phen and the heart
Phendimetrazine (Obex)
Slimming drugs and social behavior

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Cannabis.net
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhappiness?
Utopian Surgery?
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World